Acura receives $20M milestone from Pfizer; Feuerstein: Seattle Genetics is biotech's next big thing;

@FierceBiotech: For real innovation, look beyond science. Story | Follow @FierceBiotech

@JohnCFierce: Here's the PR on Acorda's acquisition of Ph2 drug. This biotech knows something about locomotor function. Smart. Item | Follow @JohnCFierce

> Acura Pharmaceuticals has received a $20 million milestone payment from Pfizer, thanks to the FDA approval of Pfizer's NDA for Oxecta. The drug uses Acura's AVERSION technology to dissuade opioid abuse. Acura release

> Adam Feuerstein explains why Seattle Genetics is the next big thing in biotech in a video for TheStreet. Video

> Bothell, WA-based SCOLR Pharma has announced the final closing of its private placement of 8 percent senior secured convertible debentures, raising $1.2 million. SCOLR release

> Inovio Pharmaceuticals has been appointed Dr. Avtar Dhillon the non-executive Chairman of the Board of Directors. Dhillon was made the Executive Chairman of the Board in 2009. Inovio release

Pharma News

@FiercePharma: Will Abbott's Niaspan fall short of blockbuster sales? Article | Follow @FiercePharma

> Dendreon's $93K cancer vax wins final CMS nod. News

> Japan ushers in big meds from AZ, GSK, Merck. Item

> Is pharma's rep among doctors on the upswing? Article

> FDA raises red flag on Depakote in pregnancy. Report

> Lundbeck to withhold Nembutal from U.S. prisons. Story

> Medicare won't drop Avastin for breast cancer. News

And Finally... An University of Gothenburg study has linked a series of novel proteins in cerebrospinal fluid to Alzheimer's disease. The proteins are found in higher quantities in patients with dementia who develop Alzheimer's than those who develop other diseases. Article

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.